Should I Buy GHRS? GHRS 2026 Analysis

Should You Buy GH Research PLC (GHRS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

15.660

1 Day change

-3.57%

52 Week Range

20.500

Analysis Updated At

2026/01/28

Not a good buy right now for a Beginner, long-term investor with $50k–$100k who wants to act immediately. Despite a bullish longer-term moving-average setup and a very positive sell-side view (RBC Outperform, $40 target), GHRS is still a pre-revenue biotech with ongoing losses, extremely high options-implied volatility, and weakening near-term momentum (bearish MACD). I would NOT initiate a new long position at today’s level.

Technical Analysis

Price/Trend: Last close 15.77 (down -0.93% vs prior close 16.21). The stock is trading below the pivot (16.421), which is a near-term negative. Momentum: MACD histogram is negative (-0.0191) and negatively expanding, suggesting weakening momentum. RSI(6) ~47.36 is neutral—no oversold bounce signal. Trend structure: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating the broader trend is still constructive, but the current pullback is working against immediate entry timing. Levels: Support S1=15.683 (very close); if this breaks, next support S2=15.228. Resistance R1=17.158 then R2=17.613. Pattern-based outlook: Similar-candlestick analysis implies mildly bearish drift (60% chance of -1.09% next day; -0.51% next week; -0.91% next month). Intellectia Proprietary Trading Signals: - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning looks aggressively call-skewed on open interest (put/call OI ratio 0.07; calls OI 8,979 vs puts OI 658), which is bullish on paper. However, actual trading activity is extremely light (today’s total volume 1; put volume 0), so sentiment is not strongly confirmed by flow. Volatility is extremely elevated (30D IV ~201.87% vs historical vol ~79.86%; IV percentile 72.4), which typically signals the market is pricing large moves and uncertainty—more consistent with speculative biotech risk than a stable long-term beginner-friendly entry.

Technical Summary

Sell

Buy

Positive Catalysts

Analyst support improving: RBC Capital raised its target to $40 from $33 (Outperform), citing optimism around long-term sales opportunity for GH
Institutional interest: Hedge funds are reported as buying, with buying amount up ~735% over the last quarter.
Technical backdrop still constructive on longer-term measures (SMA_5 > SMA_20 > SMA_200), suggesting the bigger trend has not fully broken.

Neutral/Negative Catalysts

No recent news in the last week—no fresh catalyst to reverse current weakening momentum.
Near-term technical weakness: price below pivot and MACD negative/expanding.
Business fundamentals remain early-stage: revenue still 0, and the company is loss-making; this increases long-term execution risk.
Options-implied volatility is extremely high (~202%), which aligns with elevated uncertainty and potential sharp drawdowns.
No supportive insider buying trend noted (insiders neutral).

Financial Performance

Latest quarter (2025/Q3): Revenue remains 0 (no commercialization yet). Net income improved YoY to -$14.02M (15.73% improvement), indicating some cost/expense progress, but profitability is still far away. EPS was -0.23 (still negative). Overall: improving loss profile, but still pre-revenue and dependent on future clinical/commercial execution.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Positive. On 2026-01-23, RBC Capital raised its price target to $40 from $33 and reiterated Outperform after industry symposium discussions, emphasizing long-term sales potential for GH001. Wall Street pro view (Pros): Strong upside implied by the target increase; belief in long-term commercial opportunity. Wall Street con view (Cons): The report doesn’t remove core early-stage risks (no revenue, ongoing losses), and current market pricing/volatility suggests outcomes remain uncertain. Influential/political trading: No recent congress trading data available; no politician activity indicated in the provided data.

6 Analyst Rating

Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is 28.6 USD with a low forecast of 19 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 16.240

Low

Averages

28.6

High

Current: 16.240

Low

Averages

28.6

High

RBC Capital

Outperform

maintain

$33 -> $40

AI Analysis

2026-01-23

Reason

RBC Capital

Price Target

$33 -> $40

AI Analysis

2026-01-23

maintain

Outperform

Reason

RBC Capital raised the firm's price target on GH Research to $40 from $33 and keeps an Outperform rating on the shares. Following the firm's Psychedelics Symposium and discussions with the management, payers, and doctors, RBC is increasingly optimistic on GH's long- term sales opportunity, with GH001, the analyst tells investors in a research note.

Cantor Fitzgerald

initiated

$25

2025-06-04

Reason

Cantor Fitzgerald

Price Target

$25

2025-06-04

initiated

Reason

Cantor Fitzgerald assumed coverage of GH Research with an Overweight rating and $25 price target. Data generated for psychedelics across a number of mental health disorders have been "transformational," and the unmet need is "enormous" and growing, the analyst tells investors in a research note. The firm says sees the psychedelic total addressable market ultimately reaching $50B per year, which would be roughly 1M-1.5M patients treated per year, still only modest penetration, and believes there is room for plenty of successful options and companies offering psilocybin and novel synthetic products.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GHRS

Unlock Now

GHRS Should I Buy

GHRS Should I Buy

Should You Buy GH Research PLC (GHRS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch